Program
HLX87
A development code. Also written as “HLX87 + HLX22” and “HLX87+HX22”.
In Fosun Pharma's pipeline, HER2 ADC
. Its studies are mostly in Breast Neoplasms, led by Fosun Pharma.
Furthest: phase 3, since Dec 8, 20252 company-led studies, 2 open or runningNext primary completion: Jan 15, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 22 open or running | phase 3since Dec 8, 2025 | Dec 8, 2025 | Jan 15, 2028phase 3 · NCT07294508 |
- Named in Fosun Pharma’s own pipeline as
HLX87 (HER2 ADC)
, phase 3, as of Sep 21, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 8, 2025First studies: 2 phase 3 studies in Breast NeoplasmsFirst studyNCT07294534, NCT07294508
Ahead
- Jan 15, 2028Primary completion: phase 3 study in Breast NeoplasmsNCT07294508
- Sep 30, 2028Primary completion: phase 3 study in Breast NeoplasmsNCT07294534
TargetBeta
“HER2 ADC”the company's pipeline, read by Claude · source
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07294534Breast Neoplasms | 3 | Not yet recruiting | Sep 30, 2028 | 817 |
| NCT07294508Breast Neoplasms · China | 3 | Recruiting | Jan 15, 2028 | 706 |
How it is read
Names in the registry
- “HLX87 + HLX22”, 1 entry
- “HLX87+HX22”, 1 entry
Codes read as this program: HLX87.
Conditions, from the studies’ own filings
- Breast Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.